Federal Register Notice

On Friday February 24, 2023, DEA announced that it would be publishing two Notice of Proposed Rulemakings (“NPRM”) in the Federal Register which pertain to expanding patient access to prescriptions for controlled substances via telemedicine encounters.  These two NPRMs, titled “Telemedicine prescribing of controlled substances when the practitioner and the patient have not had a prior in-person medical evaluation” DEA-407, RIN 1117-AB40 and “Expansion of induction of buprenorphine via telemedicine encounter” DEA-948, RIN 1117-AB78 published March 01, 2023, in the Federal Register. 

These NPRMs may be found at www.regulations.gov.  DEA encourages registrants to direct all comments and questions pertaining to these rulemakings directly on the proposed rules which may be found here, and here.  For more information regarding DEA’s Diversion Control Division, please visit www.DEAdiversion.usdoj.gov. 

FOR FURTHER INFORMATION CONTACT:
Scott A. Brinks, Diversion Control Division, Drug Enforcement Administration. 
Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152, Telephone: (571) 776–3882.